INTRODUCTION
Methylenedioxymethamphetamine (3,4 MDMA) is a synthetic amphetamine derivative, with a broad spectrum of neurochemical eects. It is an indirect serotonergic agonist, but also displays binding anity for dopaminergic and other neurotransmitter receptors (Solowij, 1993; McDowell and Kleber, 1994) . While its dopaminergic agonist actions are similar to those of amphetamine, its serotonergic eects are closer to LSD. In behavioural terms, MDMA also displays similarities to both amphetamine and LSD. Its sympathomimetic and alerting eects are like those of amphetamine, whereas its propensity for intensifying sensory experience make it closer to LSD (McDowell and Kleber, 1994) . Some authorities have therefore categorized 3,4-methylenedioxymethamphetamine as an hallucinogenic amphetamine, whereas others have suggested that it is more unique, and should be placed within its own putative class (Nichols, 1986; Solowij et al., 1992) . However there is a paucity of empirical data on the psychopharmacological changes generated by MDMA, particularly in relation to other drugs of abuse. The aim of this study was therefore to investigate the comparative mood pro®les for MDMA, amphetamine and LSD, as described by recreational polydrug users.
MATERIALS AND METHODS

Subjects
Twenty-one unpaid subjects were obtained using the`snowball' technique, where a small group of known drug users spread word of the study amongst friends and acquaintances (Solowij et al., 1992; Davison and Parrott, 1997) . All had used amphetamine, MDMA, and LSD on dierent occasions. Their ages ranged from 17±34 years.
Pro®le of Mood States Questionnaire (POMS)
This comprised a list of 72 mood adjectives, grouped into six bipolar mood factors (Lorr and McNair, 1980) . The response format was modi®ed to assess feeling state changes while on-drug (Parrott, 1996) . The instructions were as follows: Below are some words which describe feelings and moods. Please tick one box for each word, indicating how you most feel ON or OFF Ecstasy. If you feel the SAME while on or o Ecstasy, please tick the SAME box'. For example:
Most like this when ON-ECSTASY SAME on-and-o Ecstasy Most like this when OFF-ECSTASY Each response was scored: 0, 1, or 2. With 12 adjectives per mood subscale, a score of 12 indicated no mood change on-drug, and therefore represented baseline. The overall range of possible scores for each bipolar scale was 0±24. Three POMS questionnaires were completed, one for each drug type. Subjects were instructed that their responses for each questionnaire, should be based upon their personal experience with each type of drug. Anonymity and con®dentiality were assured.
RESULTS
The ANOVA drug factor was highly signi®cant for all six POMS mood factors (all comparisons p`0Á001). Duncan's multiple comparison tests were performed for each pair of drug conditions, and for each drug compared to baseline (Table 1) . Amphetamine signi®cantly aected three mood factors, with increased feelings of energy, elation, and con®dence ( Figure 1 ). MDMA aected four mood factors, with signi®cantly higher feelings of energy, elation, agreeableness, and con®dence. LSD led to signi®cantly higher feelings of energy and elation, together with mental confusion, uncertainty, and anxiety (Figure 1 ). The MDMA mood scores were intermediate between amphetamine and LSD on three POMS factors: energetic/ tired, con®dent/unsure, and clearheaded/confused (Figure 1) . While on the other three POMS factors, MDMA was not intermediate between amphetamine and LSD. Feelings of elation, agreeableness, and emotional composure, were all signi®cantly higher under MDMA than amphetamine or LSD (all comparisons p`0Á01; Table 1 ).
DISCUSSION
The mood pro®le for 3,4-methylenedioxymethamphetamine (MDMA), was of increased elation, 
AMP, amphetamine; MDMA, 3,4-methylenedioxymethamphetamine (Ecstasy); LSD, lysergic acid diethylamide; BASE, baseline (drug free). agreeableness, energeticness and con®dence (Figure 1 ). This was similar to previous reports. Solowij et al. (1992) noted increased feelings of energy, activation, euphoria, and con®dence, in Australian MDMA users. Peroutka et al. (1988) noted feelings of happiness, euphoria, alertness and enhanced sensuality, in American college students. Davison and Parrott (1997) documented a pro®le of increased elation, agreeableness, energeticness and mental confusion, in British Ecstasy users. The above studies also described marked physiological changes, with increased heart rate, sweating and dehydration. These can easily lead to medical emergencies, particularly in the hot and crowded conditions of raves and dances. The confused person may dehydrate through hyperthermia, or overcompensate and drink too much water, thus lethally diluting their plasma electrolytes (Maxwell et al., 1994) . The mood-elevating eects of MDMA are therefore not free from serious medical risks (Dowling et al., 1987; Henry et al., 1992; Lee, 1994; Maxwell et al., 1994; Series et al., 1994; Parrott, 1995) . Amphetamine demonstrated both alerting and euphoriant eects (Figure 1) , following its agonist actions upon the reticular formation, and dopaminergic reward systems (Ashton, 1987) . Most previous LSD research has focused upon its perceptual and cognitive eects, and its mood pro®le has rarely been studied. The current LSD data showed a mixture of bene®cial and detrimental mood changes, with increased energy and elation, combined with feelings of uncertainty, confusion and anxiety (Figure 1) . In comparative terms, MDMA was intermediate between amphetamine and LSD on three POMS factors: energeticness, con®dence, and clearheadedness. Whereas on the other three POMS factors, MDMA produced signi®cantly higher scores than both amphetamine and LSD (Figure 1 ; Table 1 ). Overall therefore, while the alerting eects of MDMA are broadly intermediate between amphetamine and LSD, its euphoriant properties seem more unique (Nichols, 1986; Liester et al., 1992; Solowij et al., 1992; Davison and Parrott, 1997) .
It should be emphasized that subjects were asked to describe how then typically felt on each type of drug; yet all three drugs can generate unpleasant experiences. Solowij et al. (1992 Solowij et al. ( , p. 1169 reported that 28 per cent of their sample had suered an:`Acute bad reaction to MDMA such as paranoia, panic, loss of reality, loss of control, anxiety, and hallucinations'. Davison and Parrott (1997) similarly noted that 25 per cent of their subjects had experienced at least one bad MDMA trip, due to: vomiting, paranoia, fear, panic, feeling immobile, confused thought, or thoughts of death (one subject now avoids all illicit drugs, following a particularly distressing MDMA experience). Prolonged psychiatric after-eects of MDMA have also been described (Lee, 1994; Maxwell et al., 1994; Series et al., 1994) . Bad trips are a common occupational hazard of LSD, while amphetamine/cocaine abusers are renowned for their paranoia, and propensity for physical violence (Angrist. 1987) .
Unpleasant mood states also occur on drug withdrawal, during neurochemical depletion. The after-eects of an amphetamine trip include feelings of fatigue, irritability, lassitude and depression. Similarly, MDMA trips are followed by feelings of lethargy, depression, irritability, insomnia, and paranoia, during serotonergic and dopaminergic depletion (Solowij et al., 1992; McDowell and Kleber, 1994) . The mood changes after an LSD trip include lassitude and nervousness, together with cognitive and perceptual¯ash-backs. The long-term neurochemical eects of repeated drug use are also a matter of concern. Cognitive performance de®cits have been demonstrated in regular MDMA users (Krystal et al., 1992; Parrott, 1997; Parrott et al., unpublished data) , and the serotonergic depletion which accompanies regular MDMA use, has worrying implications for the future health of young drug users (Ricaurte and McCann, 1992; Solowij, 1993; McDowell and Kleber, 1994;  This study suered from various methodological limitations. The data were based upon retrospective recall, so that selective memory biases may have aected subjects' reports. There was no control over what drugs had been taken (composition, purity, or strength), nor the environmental conditions (Zinberg, 1984) . Despite these problems, the overall consistency of the current ®ndings, and similarity to those described elsewhere (Peroutka et al., 1988; Liester et al., 1992; Solowij et al., 1992) , provides support for their general construct validity (Parrott, 1991) . Nevertheless, placebocontrolled MDMA trials would answer a number of crucial questions, if they were ethically sanctioned. Dose±response eects, time course and recovery pro®les, acute and chronic tolerance, inter-subject variation, expectancy, and the in¯u-ence of environmental factors, could all be usefully studied.
